Phase 1 results for IO-202, our anti-LILRB4 antibody, are now in @Bloodneoplasia. The data show promising activity in #CMML and #AML, offering new hope for patients with limited treatment options.
Read more: immune-onc.com/pr-posts/immun…
The first patient has been dosed in our global Ph 1b/2 trial evaluating IO-108 for 1st-line treatment of HCC in clinical collaboration with Roche!
A major step forward in our mission to advance cancer care. Learn more: bit.ly/4ihX9Op
We’re back from #ASH2024 and inspired by the energy and engagement around our oral presentation on IO-202 for #CMML. This is a key step toward new hope for people with this rare blood cancer.
Thank you to everyone who joined us.
ICYMI: bit.ly/3OIEI8V
Today, we are proud to present groundbreaking new Phase 1b data on IO-202 for #CMML at #ASH2024!
✔️ CR: 50% | ORR: 66.7%
✔️ High LILRB4 expression: CR: 83%; ORR: 100%
✔️ 40% bridged to transplant
✔️ Additional clinical benefits
Learn more: bit.ly/3OIEI8V
We’re proud to see @ImmuneOnc's IO-102 Ph 1 #CMML study featured in @LLSusa's announcement highlighting new data showing progress for hard-to-treat blood cancers. Looking forward to sharing more updates on the study at #ASH2024. bit.ly/3Oqvvly
Our Ph 1 data on IO-108 was published in @jitcancer !
· Durable responses in advanced solid tumors
· Promising monotherapy & combo results with pembrolizumab
· Potential to overcome resistance to checkpoint inhibitors
Read the full press release: bit.ly/4fu6e5N
We're thrilled to announce that Immune-Onc will present new IO-202 data for chronic myelomonocytic leukemia (CMML) at #ASH24! Join us to learn about the potential of our anti-LILRB4 antibody in addressing CMML, an underserved cancer with limited treatments bit.ly/40sNUW4
New from @ImmuneOnc at #EHA2024! Today, we will present additional positive interim Ph 1b expansion data for IO-202 in #CMML patients. The study shows early and sustained complete remissions among patients, regardless of their prognosis or mutation status. bit.ly/3Rs1SC7
#News: We look forward to presenting interim clinical data from our Phase 1b trial of IO-202 for the treatment of chronic myelomonocytic leukemia (#CMML) at the upcoming #EHA2024 Congress. View the press release for details: bit.ly/4bjpnoQ
Exciting News! The @SFBusinessTimes recognized our Orphan Drug Designation for IO-202 for #CMML as a recent breakthrough by women-led life sciences companies in the Bay Area. Read more here: bizjournals.com/sanfrancisco/n…
Great news! The FDA has granted IO-202 Orphan Drug Designation for the treatment of chronic myelomonocytic leukemia (CMML). Our Ph 1 study of IO-202 in combination with azacitidine is also currently enrolling newly diagnosed CMML patients. Read more here: bit.ly/48pyWQT
Excited to share a collaboration with @Roche evaluating IO-108 in combination with atezolizumab (Tecentriq®) and bevacizumab (Avastin®) for the 1st line treatment of patients with locally advanced or metastatic and/or unresectable hepatocellular carcinoma bit.ly/3I42pFk
Next week at the 3rd Tumor Myeloid-Targeted Therapies Summit in Boston, our very own Dr. Luke Chung will present encouraging Ph 1 data for IO-108, our first-in-class antibody targeting LILRB2 (ILT4). We hope to see you there (Wed., 7/19 - 1:30 PM)! bit.ly/3rhgQka
#DYK that our first-in-class humanized IgG1 monoclonal antibody, IO-202, targets the myeloid inhibitory receptor LILRB4 to reverse immune suppression in the tumor microenvironment?
Visit our first clinical data presentation showing this in action at #EHA2023.
Next Tue., May 23, our CEO @charlene_liao and CFO Chris Whitmore look forward to meeting with investors 1:1 at the 2023 Wells Fargo Virtual Private Biotech Symposium to discuss how our platform of #myeloid#checkpointinhibitors is reigniting the field of #immunotherapy. #biotech
Why are we so excited about #immunotherapy? Because we’re playing a big role in its evolution. This week at #PEGS23 our CEO, @charlene_liao discussed our scientific approach and robust pipeline targeting myeloid checkpoints. Learn more at Immune-Onc.com
We are presenting clinical data for IO-202 for the first time at #EHA2023 next month! IO-202 is our first-in-class #myeloid#checkpointinhibitor targeting LILRB4 (aka ILT3) for the treatment of #AML and #CMML. Read below for info to attend the presentation ⬇️
#DYK that myeloid checkpoints could be game-changing targets for the field of #cancerimmunotherapy? Join our CEO @charlene_liao's presentation at the @CHI_Healthtech's 2nd Annual “Emerging Targets for Oncology and Beyond” conference at #PEGS23 next week. See you there!
1K Followers 187 FollowingLeveraging Penn Medicine’s first-mover position in immunology to revolutionize routine human immune profiling for maximum impact across medical disciplines.
2K Followers 2K Followingsmall business and startup investor and 5 professional soccer teams Army Infantryman and military intelligence graduate of UC and FSU foreign affairs degree
176 Followers 302 FollowingAssociate Director of Business Development @LonzaGroup - Make better biologics and vaccine with end-to-end solution - Runner🏃♀️, Surfer🏄♀️, Drug develomp 🧬
63 Followers 519 FollowingRemote & Onsite Pharma, Biotech, Medical Device and CRO Jobs.
Post & look for jobs at https://t.co/O0ew7a61vf.
Worldwide Pharma Job board
107 Followers 691 FollowingOn a mission to make cancer a chronic disease, one we can still thrive with! The world need to realize that lung cancer is a women's problem!
576 Followers 1K FollowingConnecting life scientists and professionals since 2008, with hubs across the US. @sdbn @sfbionetwork @bcbionetwork @dcbionetwork #biotech #news #jobs #events
1K Followers 5K FollowingHi Friends,
This is our official Twitter account of Angia Rx Life Science Pvt Ltd,we are manufacturer of pharma products based from Roorkee Uttarakhand India.
4.5M Followers 460 FollowingCutting-edge research, news, commentary, and visuals from the Science family of journals. Follow @NewsfromScience for stories from our News team.
318K Followers 2K FollowingPublishing the best of biotech science and business. Find us on Bluesky, Facebook & Instagram. Part of @SpringerNature and @NaturePortfolio.
120K Followers 781 FollowingBiotech reporter @statnews. Dog ❤️er. Polk Award winner. #COYS. Said one analyst: The likes of Adam Feuerstein attack viciously. On Signal: stataf.54
12K Followers 6K FollowingCalifornia Life Sciences is the state’s most impactful life sciences membership org. advocating for the industry & its diverse innovation pipeline
55K Followers 608 FollowingThe latest global #pharma news, insights, analysis, and views providing you with an information edge. FirstWord Pharma. Where people who know first, go first.
35K Followers 2K FollowingPharmaVoice is the leading community for life sciences leaders to share their stories, voices and ideas. Subscribe at https://t.co/VQzsyqTs0b
48K Followers 2K FollowingHealthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
30K Followers 2K FollowingThe San Jose region's source for local business news & events. Part of the American City Business Journals network. Subscribe today! https://t.co/MdCLvk6fq3
44K Followers 2K FollowingThe San Francisco region's source for local business news & events. Part of the American City Business Journals network. Subscribe today! https://t.co/mSzjj3kj4a
20K Followers 5K FollowingSociety for Immunotherapy of Cancer (SITC) - Dedicated to improving cancer patient outcomes by advancing the field of tumor immunology and cancer immunotherapy.
544 Followers 157 FollowingReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics.
11K Followers 2K Following#Biotech reporter @SFBusinessTimes; hardcore @Tigers fan; once rolled a 288. Tip me: [email protected], Signal or 415-722-2678. Also find me on bluesky.
15K Followers 526 FollowingAccelerating world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world
94 Followers 103 FollowingA globally minded, tech-centric venture firm investing at the intersection of enterprise, healthcare, and consumer opportunities.
2K Followers 345 FollowingDoing the most for more people with blood cancer.
We are the Research team of @bloodcancerutd.
We're all about cutting-edge blood cancer research to find a cure
61 Followers 106 FollowingOTM is responsible for licensing and commercializing cutting edge research developed at UTHealth. Please contact us at [email protected]
16K Followers 2K FollowingThe leading voice for decision-makers throughout the global biopharma ecosystem. Follow us on LinkedIn for exclusive insights & analysis: https://t.co/V33Z1gfUfZ
224K Followers 4K FollowingThe U.S. government’s agency for cancer research. Part of @NIH. Engagement ≠ endorsement. Questions about cancer? Reach us here: https://t.co/yQAi9x4Obg
2.2M Followers 2K FollowingNature Portfolio’s high-quality products and services across the life, physical, chemical and applied sciences is dedicated to serving the scientific community.
71K Followers 108 Following47 yrs before the mast. Invented FierceBiotech, founded Endpoints News w/ 243,000 subs. Devoting time to the big showdown with Merkel cell carcinoma . We'll see
32K Followers 2K FollowingAlbert Einstein College of Medicine: Educating students to become caring, skilled physicians and fostering biomedical and translational research.